【24h】

Inhibition of canonical WNT signaling attenuates human leiomyoma cell growth

机译:规范的WNT信号的抑制减弱了人类平滑肌瘤细胞的生长

获取原文
获取原文并翻译 | 示例
           

摘要

Objective To assess the effect of three WNT/β-catenin pathway inhibitors - inhibitor of β-catenin and TCF4 (ICAT), niclosamide, and XAV939 - on the proliferation of primary cultures of human uterine leiomyoma cells. Design Prospective study of human leiomyoma cells obtained from myomectomy or hysterectomy. Setting University research laboratory. Patient(s) Women (n = 38) aged 27-53 years undergoing surgery. Intervention(s) Adenoviral ICAT overexpression or treatment with varying concentrations of niclosamide or XAV939. Main Outcome Measure(s) Cell proliferation, cell death, WNT/-catenin target gene expression or reporter gene regulation, β-catenin levels, and cellular localization. Result(s) Inhibitor of β-catenin and TCF4, niclosamide, or XAV939 inhibit WNT/β-catenin pathway activation and exert antiproliferative effects in primary cultures of human leiomyoma cells. Conclusion(s) Three WNT/-catenin pathway inhibitors specifically block human leiomyoma growth and proliferation, suggesting that the canonical WNT pathway may be a potential therapeutic target for the treatment of uterine leiomyoma. Our findings provide rationale for further preclinical and clinical evaluation of ICAT, niclosamide, and XAV939 as candidate antitumor agents for uterine leiomyoma.
机译:目的评估三种WNT /β-catenin途径抑制剂-β-catenin和TCF4抑制剂(ICAT),niclosamide和XAV939对人子宫平滑肌瘤细胞原代培养物增殖的影响。设计从子宫肌瘤切除术或子宫切除术获得的人类平滑肌瘤细胞的前瞻性研究。设置大学研究实验室。患者(n = 38),年龄27-53岁,正在接受手术。干预措施腺病毒ICAT过表达或用不同浓度的尼克洛酰胺或XAV939治疗。主要指标:细胞增殖,细胞死亡,WNT /连环蛋白靶基因表达或报道基因调控,β-连环蛋白水平和细胞定位。结果β-catenin和TCF4,niclosamide或XAV939的抑制剂在人平滑肌瘤细胞的原代培养物中抑制WNT /β-catenin途径的活化并发挥抗增殖作用。结论三种WNT / -catenin途径抑制剂可特异性阻断人平滑肌瘤的生长和增殖,这表明经典的WNT途径可能是治疗子宫平滑肌瘤的潜在治疗靶标。我们的发现为进一步将ICAT,niclosamide和XAV939作为子宫平滑肌瘤的候选抗肿瘤药进行临床前和临床评估提供了依据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号